Initial Diastolic Dysfunction is a Powerful Predictor of 5-year Mortality in Peripheral Arterial Disease Patients undergoing Percutaneous Transluminal Angioplasty

Kyung-Hee Kim
Sejong General Hospital

Seung Woon Rha (✉ swrha617@yahoo.co.kr)
Korea University Guro Hospital  https://orcid.org/0000-0001-9456-9852

Byoung Geol Choi
Korea University Guro Hospital

Jae-Kyung Byun
Korea University Guro Hospital

Woohyeun Kim
Korea University Guro Hospital

Cheol Ung Choi
Korea University Guro Hospital

Hong-Seog Seo
Korea University Guro Hospital

Research

Keywords: Peripheral Artery Disease, Heart Failure, Systolic Dysfunction, Diastolic Dysfunction

DOI: https://doi.org/10.21203/rs.3.rs-41677/v1

License: Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Peripheral arterial disease (PAD) and heart failure share common risks and are associated with increased morbidity and mortality. However, it is unknown whether cardiac function can be an independent predictor of long-term mortality in patients with PAD.

Methods

In total, 902 patients who underwent percutaneous transluminal angioplasty for PAD were enrolled. The patients were categorized into three groups according to the left ventricular ejection fraction (LVEF): reduced EF (< 40%, n = 62); mid-range EF (40–49%, n = 76); and preserved EF (≥ 50%, n = 764). Echocardiographic (EF, ratio of mitral inflow velocity to annular velocity E/e_0 ≥ 15, and others) and clinical parameters were tested using stepwise logistic regression analysis to determine independent predictors of 5-year mortality.

Results

A higher proportion of patients with reduced EF had ischemic heart disease than those with preserved EF (77.4% vs. 56.8%, p < 0.001). Up to 5 years, patients with reduced EF and mid-range EF showed a higher incidence of total death than those with normal EF. However, there was no difference in the incidence of myocardial infarction, stroke, and revascularization among the three groups. After multivariable adjustment, the ratio of E/e_0 ≥ 15 was the only strong predictor of total mortality (hazard ratio, 6.14; 95% confidence interval, 3.7–10.1;p < 0.01).

Conclusion

Patients with PAD and reduced EF undergoing PTA had a higher incidence of total death during the 5-year follow-up. Initial tissue Doppler E/e_0 ≥ 15, a non-invasive estimate of left atrial filling pressure, was the only independent predictor of long-term mortality.

Introduction

Lower extremity peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis and is associated with increased cardiovascular morbidity and mortality [1][2]. Patients with PAD have a 3-fold increased risk of death from all causes and a 6-fold increased risk of death from cardiovascular disease within a 10-year period when compared with patients without PAD [3]. An estimated > 200 million people...
have PAD worldwide, with a spectrum of symptoms ranging from none to severe 4)5). Despite the high morbidity and mortality, patients with PAD are often underdiagnosed and undertreated.

Although the reason for the poor prognosis in patients with PAD is unknown, high prevalence of coexistent cardiovascular disease (coronary artery disease, chronic heart failure [HF], or stroke) has frequently been mentioned as the likely cause of PAD occurrence 6)7). Patients with PAD have a high comorbidity burden, which has significant implications for clinical management.

However, the cardiac function of patients with PAD has not been studied systematically. Limited data are available on the association between cardiac function and PAD, especially in patients who underwent percutaneous transluminal angioplasty (PTA). In addition, diastolic dysfunction has not been yet reported in patients with PAD who underwent PTA, whereas left ventricular (LV) systolic dysfunction has been described8). We aimed to evaluate the association between PAD and heart failure in patients with symptomatic PAD who underwent PTA. We also analyzed the effect of these abnormal cardiac findings on long-term cardiovascular outcomes in these patients.

**Method**

We obtained data from the PTA registry of Korea University Guro Hospital (KUGH), Seoul, South Korea. This registry has been described in detail in previous studies. This single-center, prospective, all-comers registry was started in 2004 and designed to reflect real-world clinical practice. The study protocol was approved by the Medical Device Institutional Review Board of KUGH (protocol #MD12018). The study population included a total of 902 consecutive patients with symptomatic PAD who underwent PTA of the iliac, femoral, popliteal, tibial, and peroneal arteries from September 2004 to August 2017. The data were collected by trained study coordinators using standardized case report forms 9).

**Coronary and Peripheral Angiography and Revascularization**

Standard techniques were used for PTA. Coronary and peripheral angioplasties were performed with a crossover approach or an anterograde ipsilateral femoral approach using 5 ~ 6 French sheaths. If there are significant coronary fixed stenosis (> 70% diameter stenosis), direct percutaneous coronary intervention (PCI) or staged PCI within the same hospitalization period was recommended and performed. Post-intervention dual antiplatelet therapy with aspirin 100 mg and clopidogrel 75 mg once daily or additional cilostazol 100 mg twice daily was given for at least 6 months, while aspirin 100 mg and/or clopidogrel 75 mg was given daily thereafter. Medications beneficial for cardiovascular health, including renin-angiotensin-aldosterone blockers, beta-blockers, and statins, were also prescribed according to practice guidelines.

**Echocardiography**

All patients underwent echocardiography examinations. Patients with transthoracic echocardiography (TTE) findings not suitable for the quantitative assessment of LV ejection fraction (LVEF) or diastology
were excluded. The ratio of the transmitral Doppler E wave velocity and the early diastolic velocity (E/e') at the septal annulus (E/e' ratio) was evaluated to estimate LV filling pressure. One best LVEF value for each patient was determined using a hierarchical approach: volumetric LVEF calculated using the 2D Simpson's biplane method was preferred, followed by other calculated LVEF methods, followed by visual estimation if these other methods were unavailable. We divided the patients into three groups according to LVEF values: preserved LV function, LVEF ≥ 50%; mid-range LV function, 40% ≤ LVEF < 50%; and reduced LV function, LVEF < 40%. LV mass was calculated using ASE formula 10). LV regional wall motion was analyzed visually using the standard 16-segment model. Pulmonary artery systolic pressure (PASP) was estimated from the peak tricuspid regurgitation (TR) velocity obtained using continuous-wave Doppler echocardiography and estimated right atrial pressure as previously described 11).

**Baseline Clinical Characteristics**

Baseline patient characteristics were determined based on chart review and included age, sex, hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, coronary artery disease (CAD), renal insufficiency, current smoking, and family history of CAD.

**Study Endpoints and Major Clinical Outcomes**

The primary study endpoint was all-cause death, and the key secondary study endpoint was patient-oriented composite outcome (composite of all-cause death, any myocardial infarction [MI], stroke, or any repeat revascularization) at the 5-year or last follow-up. The cause of all deaths was considered cardiac unless an undisputed non-cardiac cause was present. MI was defined as symptom recurrence or the presence of electrocardiographic changes in association with an increase in cardiac biomarker levels above the upper limit of normal; cases of periprocedural MI were not included as clinical outcomes. Stroke was defined as the presence of neurological deficits confirmed by a neurologist on the basis of imaging study findings. Clinically driven revascularization that occurred after discharge from the index hospitalization was coded as a repeat revascularization event.

**Statistical Analysis**

Continuous variables are presented as mean and standard deviation when normally distributed or as median when not normally distributed. Demographic and echocardiographic factors were analyzed among groups using analysis of variance for continuous variables and chi-square for categorical variables. Kaplan-Meier and Cox regression analyses were used to determine associations between echocardiographic variables in patients with PAD and outcomes during the 5-year follow-up. Age, sex, hypertension, diabetes mellitus, dyslipidemia, CAD, and clinically important echocardiographic findings found to be univariate predictors of mortality were entered into multivariate models as predictors of mortality and for secondary study endpoints. A restricted cubic spline function allowed us to estimate a smooth nonlinear relationship between echocardiographic parameters and outcome in a regression model 12). All statistical tests were 2-tailed, with probability values < 0.05 considered significant. All data analyses were performed using SPSS for Windows version 20 (SPSS, Inc., Chicago, IL, USA).
Results

Baseline Characteristics and Echocardiographic Findings according to LV Function

The mean patient age was 68 ± 10 years; 77% of the patients were male. The patients’ baseline characteristics and cardiovascular risk factors according to LVEF are listed in Table 1. Compared with patients with preserved EF, a higher proportion of patients with reduced EF had renal insufficiency, atrial fibrillation, and CAD. The other baseline characteristics were similar between groups. Over 80% of the enrolled patients underwent coronary angiography, and the reduced EF group had more left main lesions or multi-vessel disease. However, the limb characteristics were similar among the groups (supplementary Table 1). The echocardiographic findings are listed in Table 2. The reduced EF group had more cases of RWMA, mitral regurgitation, elevated E/e\(\text{a}\), and elevated PASP. Valve calcification descriptions by echocardiography specialist cardiologists were similar among groups (Table 2).
Table 1
Baseline clinical characteristics according to EF

| Variables, n (%) | Reduced EF (n = 62 pts) | Mid-range EF (n = 76 pts) | Preserved EF (n = 764 pts) | p value |
|------------------|------------------------|---------------------------|---------------------------|---------|
| **Baseline characteristic** | | | | |
| Sex, male | 48 (77.4) | 62 (81.5) | 590 (77.2) | 0.685 |
| Age, year | 66.3 ± 10.2 | 68.3 ± 9.6 | 68.0 ± 10.7 | 0.255 |
| Body mass index | 22.2 ± 3.3 | 23.4 ± 3.5 | 23.1 ± 3.3 | 0.511 |
| **Blood pressure, mmHg** | | | | |
| Systolic | 138.2 ± 25.1 | 143.2 ± 30.1 | 143.5 ± 24.7 | 0.308 |
| Diastolic | 72.6 ± 12.0 | 73.9 ± 15.4 | 72.4 ± 26.3 | 0.107 |
| **Heart rate, beats per minute** | | | | |
| | 84.4 ± 19.0 | 80.8 ± 21.9 | 78.7 ± 13.9 | 0.052 |
| **Initial diagnosis** | | | | |
| Wound | 43 (69.3) | 39 (51.3) | 481 (62.9) | 0.069 |
| Gangrene | 18 (29.0) | 15 (19.7) | 213 (27.8) | 0.299 |
| Claudication | 6 (9.6) | 17 (22.3) | 160 (20.9) | 0.094 |
| Resting pain | 7 (11.2) | 11 (14.4) | 88 (11.5) | 0.742 |
| Berger’s disease | 2 (3.2) | 0 (0.0) | 20 (2.6) | 0.341 |
| **Patient risks** | | | | |
| Hypertension | 46 (74.1) | 56 (73.6) | 541 (70.8) | 0.758 |
| Diabetes mellitus | 46 (74.1) | 47 (61.8) | 570 (74.6) | 0.055 |
| Medications | 43 (69.3) | 39 (51.3) | 488 (63.8) | 0.056 |
| Insulin | 20 (32.2) | 21 (27.6) | 249 (32.5) | 0.677 |
| Dietary | 0 (0.0) | 4 (5.2) | 22 (2.8) | 0.199 |
| Duration, years | 19.8 ± 10.4 | 13.6 ± 11.3 | 16.3 ± 11.8 | 0.935 |
| Dyslipidemia | 9 (14.5) | 7 (9.2) | 106 (13.8) | 0.511 |
| Stroke | 17 (27.4) | 15 (19.7) | 127 (16.6) | 0.088 |

AF, atrial fibrillation; CABG, coronary artery bypass grafting; EF, ejection fraction; PCI, percutaneous coronary intervention; PTA, percutaneous transluminal angioplasty

Data are shown as mean ± SD or number (percentage).
| Variables, n (%)                      | Reduced EF (n = 62 pts) | Mid-range EF (n = 76 pts) | Preserved EF (n = 764 pts) | p value |
|--------------------------------------|-------------------------|---------------------------|-----------------------------|---------|
| Hemorrhage                           | 2 (3.2)                 | 2 (2.6)                   | 15 (1.9)                    | 0.545   |
| Ischemia                             | 15 (24.1)               | 13 (17.1)                 | 112 (14.6)                  | 0.127   |
| Chronic renal insufficiency          | 31 (50.0)               | 29 (38.1)                 | 209 (27.3)                  | < 0.001 |
| Dialysis                             | 20 (32.2)               | 20 (26.3)                 | 125 (16.3)                  | 0.001   |
| Atrial fibrillation                  | 16 (25.8)               | 15 (19.7)                 | 56 (7.3)                    | < 0.001 |
| Persistent or permanent AF           | 9 (14.5)                | 9 (11.8)                  | 28 (3.6)                    | < 0.001 |
| History of smoking                   | 28 (45.1)               | 47 (61.8)                 | 392 (51.3)                  | 0.120   |
| Current smoker                       | 13 (20.9)               | 31 (40.7)                 | 248 (32.4)                  | 0.046   |
| Alcohol consumption                  | 14 (22.5)               | 20 (26.3)                 | 236 (30.8)                  | 0.300   |
| Currently                            | 6 (9.6)                 | 17 (22.3)                 | 183 (23.9)                  | 0.036   |
| Coronary artery disease              | 48 (77.4)               | 57 (75.0)                 | 434 (56.8)                  | < 0.001 |
| Prior CABG                           | 7 (11.2)                | 4 (5.2)                   | 28 (3.6)                    | 0.021   |
| Prior PCI                            | 20 (32.2)               | 23 (30.2)                 | 171 (22.3)                  | 0.080   |
| PCI during PTA                       | 23 (37.0)               | 27 (35.5)                 | 186 (24.3)                  | 0.014   |

AF, atrial fibrillation; CABG, coronary artery bypass grafting; EF, ejection fraction; PCI, percutaneous coronary intervention; PTA, percutaneous transluminal angioplasty

Data are shown as mean ± SD or number (percentage).
### Table 2
Baseline echocardiographic parameters

| Echocardiographic variables, n (%) | Reduced EF (n = 62 pts) | Mid-range EF (n = 76 pts) | Preserved EF (n = 764 pts) | p value |
|-----------------------------------|-------------------------|---------------------------|---------------------------|---------|
| LV ejection fraction, %           | 33.2 ± 7.7              | 48.3 ± 4.0                | 63.8 ± 3.3                | < 0.001 |
| Regional wall motion abnormalities| 55 (88.7)               | 59 (77.6)                 | 67 (8.7)                  | < 0.001 |
| LAD                               | 48 (77.4)               | 29 (38.1)                 | 21 (2.7)                  | < 0.001 |
| LCX                               | 34 (54.8)               | 30 (39.4)                 | 20 (2.6)                  | < 0.001 |
| RCA                               | 42 (67.7)               | 36 (47.3)                 | 40 (5.2)                  | < 0.001 |
| Mitral annular calcification*     | 12 (19.3)               | 13 (17.1)                 | 107 (14)                  | 0.423   |
| Aortic valve calcification*       | 9 (14.5)                | 9 (11.8)                  | 82 (10.7)                 | 0.644   |
| Mitral regurgitation†             | 28 (45.1)               | 21 (27.6)                 | 128 (16.7)                | < 0.001 |
| Aortic valve regurgitation†       | 15 (24.1)               | 15 (19.7)                 | 130 (17.0)                | 0.324   |
| Tricuspid valve regurgitation‡    | 14 (22.5)               | 7 (9.2)                   | 65 (8.5)                  | 0.001   |
| Left ventricular hypertrophy§     | 24 (38.7)               | 31 (40.7)                 | 187 (24.5)                | 0.001   |
| LV diastolic dysfunction grade#   | 0.96 ± 0.78             | 0.85 ± 0.60               | 0.88 ± 0.4                | 0.902   |
| E/e ratio                         | 20.6 ± 10.0             | 15.4 ± 7.0                | 13.0 ± 5.3                | < 0.001 |
| PASP, mmHg                        | 37.8 ± 12.3             | 33.1 ± 9.0                | 31.5 ± 8.2                | < 0.001 |

*Evaluation by the echocardiography specialist

†More than mild

‡Reduced EF patient group had more than moderate tricuspid regurgitation.

§Left ventricular hypertrophy (LVH) was defined as increased LV mass index (LVMi) (≥ 96 g/m² in females, ≥ 116 g/m² in males).

# Diastolic dysfunction is considered in our laboratory when Doppler inflow is consistent with a normal pattern (1 point), abnormal relaxation (1 point), pseudonormalization (2 points), or restrictive patterns (3 points).

LAD, left anterior descending artery; LCx, left circumflex artery; LV, left ventricle; PASP, pulmonary artery systolic pressure; RCA, right coronary artery

**In-Hospital Complications according to LV Function**

Reduced EF was associated with a higher incidence of red blood cell transfusion (p = 0.025), post-procedural aneurysm (p = 0.009), and significantly longer stay in the intensive care unit (ICU, p < 0.001) than the other LVEF types (supplementary Table 2).
All-Cause Mortality and Major Cardiovascular Events according to EF

The overall 30-day postoperative mortality rate was 2.0%. The mortality and cardiovascular morbidity rates did not differ significantly according to EF at 30 days (supplementary Table 2). During a median follow-up of 5 years, 140 total cardiovascular events occurred: 81 deaths, 8 MIs, 48 percutaneous coronary intervention (PCI) and 28 cerebral infarctions. The causes of death were stroke, MI, HF aggravation, or sudden cardiac death. Despite our best efforts, we could not identify the causes of 29 cases of sudden death. Total deaths were higher in the reduced EF group (n = 12 [19.7%]) than in the preserved EF group (n = 59 [8.9%]). Kaplan-Meier curves showed significant differences in survival among each of the two groups according to EF (reduced EF vs. preserved EF, p < 0.01; mid-range EF vs. preserved EF, p < 0.01; Fig. 1A). However, there was no significant difference in survival between the reduced and mid-range EF groups. Similar trends were found in total cardiovascular events: these events were 1.4 time more common in patients with reduced EF than in those with preserved EF (reduced EF vs. preserved EF, p = 0.04; Fig. 1B).

Predictors of All-Cause Mortality and Major Cardiovascular Events

The independent predictors of long-term mortality and combined events were identified using multiple stepwise Cox regression analysis (Fig. 2). After adjustment for age, chronic kidney disease, and HbA1c values, EF remained the only significant predictor of all-cause mortality (hazard ratio [HR], 0.96; 95% CI, 0.96–0.99; p = 0.04]. Interestingly, after additional adjustment for other variables, E/e' and longer ICU stay were independent predictors of all-cause mortality (E/e': HR, 1.11; 95% CI, 1.07–1.16; p < 0.001; and longer ICU stay: HR, 1.06; 95% CI, 1.03–1.09; p < 0.01; Fig. 1A). Heart rate was the other independent predictor of mortality (HR, 1.02; 95% CI, 1.00–1.04; p = 0.01). However, heart rate was not an independent predictor of major cardiovascular events (Fig. 2B). Each of these models was then re-run with the sequential replacement of E/e' with left atrial (LA) size, transmitral E wave velocity, transmitral E/A ratio, PASP, and tissue Doppler e' velocity. None of these measures significantly predicted all-cause mortality or major cardiovascular events with adjustment for covariates. E/e' remained the only significant echocardiographic predictor of risk.

All-Cause Mortality and Major Cardiovascular Events according to E/e'

To estimate a smooth nonlinear relationship between E/e' and outcome in a regression model, we used a restricted cubic spline function. Figure 3 shows the predicted 5-year probability of death as a function of E/e' using splines and by varying the degrees of freedom. Mortality rate was increased abruptly after the range of E/e' was over 15. E/e' values were subsequently divided into two groups for Kaplan-Meier survival analysis (E/e' < 15 vs. E/e' ≥ 15). Using the log-rank test, we found that patients with E/e' ≥ 15 had more than 6 times higher risk of mortality (Fig. 4A) as those with E/e' < 15 (HR, 6.14; 95% CI, 3.7–
Similarly, all-cause cardiovascular events were 2.8 times more common (95% CI, 2.0–4.0; \( p < 0.01 \)) in patients with \( E/e \geq 15 \) than in patients with \( E/e < 15 \) (Fig. 4B).

**Survival Analysis in Patients with Preserved EF**

Most of the patients (\( n = 764 \) [85%]) had preserved EF. Additional analysis was performed considering only patients with preserved EF to confirm that \( E/e \) was the most important echocardiogram variable in this group. Similarly, \( E/e \) was found to be an independent predictor of all-cause mortality and major cardiovascular events in the subgroup of patients with preserved EF (HR, 1.12; 95% CI, 1.07–1.17 for all-cause mortality; HR, 1.07; 95% CI, 1.03–1.12 for major cardiovascular events; \( p < 0.01 \)). Kaplan-Meier curves showed significant intergroup differences according to \( E/e \) cut-off values (\( p < 0.001 \); Figs. 5A, 5B).

The 5-year survival rate was 97.1% among patients with \( E/e < 15 \), compared to the 81% observed among those with \( E/e \geq 15 \) and preserved EF. Patients with higher \( E/e \) (\( \geq 15 \)) had a 6.8 times higher risk of death (HR, 6.8; 95% CI, 3.8–12.3; \( p < 0.01 \)) and a 3.1 times higher risk of a major cardiovascular event (HR, 3.1; 95% CI, 2.1–4.5; \( p < 0.01 \)). Patients with \( E/e \geq 15 \) were more likely to have multi-vessel disease (43% for \( E/e \geq 15 \) vs. 28% for \( E/e < 15 \); \( p < 0.01 \)), chronic total occlusion (11% for \( E/e \geq 15 \) vs. 5.5% for \( E/e < 15 \); \( p = 0.02 \)), elevated creatinine (2.8 ± 3.1 mg/dL for \( E/e \geq 15 \) vs. 1.6 ± 2.0 mg/dL for \( E/e < 15 \); \( p < 0.01 \)), and longer ICU stay (1.2 ± 5.2 days for \( E/e \geq 15 \) vs. 0.5 ± 2.5 days for \( E/e < 15 \); \( p = 0.04 \)). Other variables were similar between the two groups.

**Discussion**

There were three main findings of the present study in patients with PAD who underwent PTA. First, patients with PAD undergoing PTA with reduced LVEF had higher incidence of total death during the 5-year follow-up. Second, an initial tissue Doppler \( E/e \geq 15 \), a non-invasive estimate of high LA filling pressure, was the only independent predictor of long-term mortality. Third, patients with preserved EF who have high LV filling pressure and PAD might be at increased risk of myocardial ischemia, which was related to a higher 5-year mortality rate. To the best of our knowledge, this is the first study to demonstrate echocardiographic prognostic predictors in patients with PAD undergoing PTA during long-term follow-up.

**LV Systolic Dysfunction and PAD**

The presence of PAD is associated with a 2-fold increase in the prevalence of HF. Given that HF and PAD share many risk factors including increased age, diabetes, smoking, atherosclerosis, and poor renal function, it is not surprising that the prevalence of LV systolic dysfunction in patients with PAD is 5.3–13.9% [5,13]. The association between PAD and cardiovascular disease and the increasing prevalence of HF in industrialized countries suggest that PAD is an important medical concern in patients with HF. In this study, over 70% of patients had hypertension and diabetes mellitus and approximately 50% of patients were smokers. Among patients with PAD who underwent PTA, 6.8% had reduced LV systolic function (\( \leq 40\% \)), whereas 15% had LV systolic dysfunction including mid-range EF (EF \( \leq 50\% \)); this prevalence of LV systolic dysfunction was similar to those reported in other studies. Patients with LV
dysfunction had increased chronic renal insufficiency and atrial fibrillation. However, in 2002, Kelly et al. reported a 28% prevalence of moderate or greater LV systolic dysfunction in 255 patients with PAD. Although the characteristics of their patients were similar to those of our patients in terms of age, sex, and prevalence of ischemic heart disease, the patients in their study were considerably more often current smokers (78%) and had different ethnicities. Our study findings demonstrate that the prevalence and burden of CAD were high among patients with LV systolic dysfunction who had PAD (77.4% of those with reduced EF vs. 56.8% of those with preserved EF; p < 0.001) and LV dysfunction was associated with an increased risk of mortality and major cardiovascular events in patients with PAD who underwent PTA. Based on current guidelines, patients who are smokers and have known CAD and/or diabetes mellitus should undergo an ABI assessment to screen the presence ofPAD. Obtaining ABI measurements in these patients at risk and with concomitant systolic HF will enhance PAD detection in this specific population. Similarly, patients with symptomatic PAD confirmed by a low ABI must be referred for echocardiography to screen LV dysfunction and detect RWMA. Ward et al. reported that, among patients with symptomatic PAD referred for echocardiography, there was a high prevalence of clinically important echocardiographic findings, including LV dysfunction. In addition, evaluation of the coronary arteries along with subsequent optimal treatment of patients of PAD who underwent PTA may improve survival. However, current indications for screening TTE in patients with PAD are limited. Prospective echocardiographic screening studies and detection of LV dysfunction are warranted in patients with symptomatic PAD.

LV Diastolic Dysfunction and PAD

Another interesting finding in our study is the association of diastolic dysfunction and long-term cardiovascular outcomes in patients with PAD. We have confirmed that E/e' is the most important variable affecting survival rates in all patients with PAD. As reduced LV function has some correlation with E/e', the analysis was conducted again only in patients with preserved EF. In this study, E/e' was found to be an independent predictor of all-cause mortality and major cardiovascular events in patients with preserved EF (HR, 1.12; 95% CI, 1.07–1.17 for all-cause mortality; HR, 1.07; 95% CI, 1.03–1.12 for major cardiovascular events; p < 0.01). Some meta-analyses reported that PAD and HF are associated with increased mortality, hospitalization, and adverse health outcomes. However, the studies included in these analyses delineated HF with regard to clinically apparent systolic dysfunction. Asymptomatic patients with diastolic HF or structural heart changes were not included in those reviews. Yamasaki et al. suggested the association of diastolic dysfunction in patients with PAD. However, the number of patients in that study was small (n = 120), and the relationship between PAD and LV diastolic function remains unclear. Yanaka et al. evaluated LV diastolic function using echocardiography in 1,121 patients and applied the American Society of Echocardiography/European Association of Cardiovascular Imaging guidelines for the diagnosis of LV diastolic dysfunction. They showed a higher prevalence of LV diastolic dysfunction in patients with PAD (n = 200) regardless of the severity of PAD (non-PAD, n = 921). Additionally, multivariate logistic regression analysis showed that PAD was an independent predictor of LV diastolic dysfunction (adjusted OR, 1.77; p = 0.01). They showed that the prevalence of LV diastolic dysfunction was higher in patients with PAD than in those without PAD. These findings suggest
that patients with PAD should be evaluated for LV systolic and diastolic function in echocardiography. However, the authors did not imply the role of diastolic dysfunction in survival among patients with PAD, and the number of patients with PAD was relatively small (n = 200) to evaluate clinical outcome differences. In our study, we enrolled 764 patients with significant and symptomatic PAD who had preserved EF and who underwent PTA, and the mean E/eᵦ was 13.0 ± 5.3. This value is relatively higher than that of normal healthy people²⁰. Among patients with preserved EF, the 5-year mortality rate was 2.9% in those with E/eᵦ < 15 (n = 15 of 525), whereas it was high, that is, 19%, in those with E/eᵦ ≥ 15 (n = 44 of 239). This result has a very important clinical interpretation. In patients with PAD and HF, claudicating calf pain and wounds from critical limb ischemia limits their ability to exercise and potentially precludes them from achieving exercise training. Moreover, as reported by Fowkes et al., patients with PAD are often asymptomatic, but even when symptoms are present, it may be extremely difficult for some patients with HF to discern claudication symptoms from fatigue owing to a chronic low output state or poor effort tolerance²¹. Therefore, PAD can often be missed in the risk stratification of patients with HF and functional limitations. Because of functional limitations, many patients with HF may not ambulate to the extent to which symptoms of PAD occur, thereby precluding its identification. The inspection and recognition of diastolic function in patients with PAD is essential because most physicians recognize reduced EF to a certain extent, and preserved EF can be confirmed on normal ultrasonography.

**Why Would E/eᵦ Predict Cardiovascular Outcomes?**

An elevated E/eᵦ is a marker for high LV filling pressure²². Using a cut-off of > 15 for an elevated medial E/eᵦ ratio with exercise, the sensitivity and specificity for predicting elevated LV filling pressure (measured invasively) were in excess of 80–85%, similar to the diagnostic accuracy of myocardial ischemia with stress echocardiography and quite acceptable for clinical practice²³. An elevated E/eᵦ is a strong predictor of death following MI²⁴ and superior to other clinical or echocardiographic features. More recently, it was also demonstrated to predict cardiac events in subjects following coronary angiography and survival in those with established cardiac arrhythmias, but the predictor has not been examined prospectively in terms of primary prevention until now. One possible explanation is that the cumulative burden of atherosclerosis per patient is proportionate to the degree of diastolic dysfunction. Therefore, this measure may act as a surrogate for the overall effect of PAD on the myocardium, which, in turn, may predict adverse cardiovascular outcomes. In our study, patients with preserved EF and elevated E/eᵦ were more likely to have multi-vessel disease (43% for E/eᵦ ≥ 15 vs. 28% E/eᵦ < 15; p < 0.01) and chronic total occlusion (11% for E/eᵦ ≥ 15 vs. 5.5% E/eᵦ < 15; p = 0.02). Hidden ischemic insult might be a cause for high LV filling pressure and eventual mortality.

**Limitations**

This study has several limitations. First, it was conducted in a single tertiary referral hospital. Although we prospectively enrolled all consecutive patients, referral bias could not be excluded; thus, the results might be difficult to generalize. However, considering the wide range of clinical and echocardiographic
parameters in our study population, the validity of our study might not be altered. Second, this was a retrospective investigation, and our patient population was a subgroup selected from overall patients who had undergone routine echocardiography with angiography; thus, some selection bias is unavoidable.

**Conclusions**

Patients with symptomatic significant PAD and reduced LVEF had a higher incidence of total mortality during the 5-year follow-up. In addition, diastolic dysfunction was the only independent predictor of long-term mortality in patients with PAD. These findings suggest that the systolic and diastolic function of patients with PAD should be evaluated. In patients with diastolic dysfunction, presence of coexisting CAD should be cautiously evaluated and monitored during follow-up.

**Abbreviations**

EF: ejection fraction  
HF: heart failure  
LV: left ventricle  
MI: myocardial infarction  
PAD: peripheral arterial disease  
PCI: percutaneous coronary intervention  
PTA: percutaneous transluminal angioplasty  
RWMA: regional wall motion abnormality  
TTE: transthoracic echocardiography

**Declarations**

- Ethical Approval and Consent to participate: It is approved by the hospital's IRB. Informed consent to participate in the study were obtained from participants.

- Consent for publication: All authors read and approved the final manuscript

- Availability of data and materials: All data can be checked by sending an email to Correspondence.

- Competing interests: none

- Funding: none
Authors' contributions: KHK and SWR contributed to the idea and design of this study, prepared and verified the clinical coding, analyzed the data, wrote the first draft, and contributed to the subsequent drafts. BGC, JKB, WHK prepared and verified the clinical coding and analyzed the data. BGC, JKB, CUC, and HSS contributed to the data collection and revised the manuscript. KHK and SWR are the principal investigators and contributed to the idea and design of this study, interpreted and analyzed the data, and contributed to the subsequent drafts. All authors have read and approved the final version for publication.

Acknowledgements: None of the authors have any financial relationships with any company or any other bias or conflict of interest to declare.

References

1. Feringa HH, Bax JJ, Hoeks S, et al. A prognostic risk index for long-term mortality in patients with peripheral arterial disease. Arch Intern Med. 2007;167:2482–9.
2. Diehm C, Allenberg JR, Pittrow D, et al. CLINICAL PERSPECTIVE Circulation. 2009;120:2053–61.
3. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–6.
4. Savji N, Rockman CB, Skolnick AH, et al. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol. 2013;61:1736–43.
5. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. Jama. 2001;286:1317–24.
6. Jones WS, Clare R, Ellis SJ, et al. Effect of peripheral arterial disease on functional and clinical outcomes in patients with heart failure (from HF-ACTION). The American journal of cardiology. 2011;108:380–4.
7. Inglis SC, McMurray JJ, Böhm M, et al. Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). Eur J Heart Fail. 2010;12:698–705.
8. Ahmed MI, Aronow WS, Criqui MH, et al. Effects of peripheral arterial disease on outcomes in advanced chronic systolic heart failure: a propensity-matched study. Circulation: Heart Failure. 2010;3:118–24.
9. Lee MS, Rha S-W, Han SK, et al. Gender differences in endovascular revascularization for peripheral arterial disease. In: VDM. P:117 – 25, 2015.
10. Mizukoshi K, Takeuchi M, Nagata Y, et al. Normal values of left ventricular mass index assessed by transthoracic three-dimensional echocardiography. J Am Soc Echocardiogr. 2016;29:51–61.
11. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation. 2001;104:2797–802.
12. Harre FE Jr, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. JNCI: Journal of the National Cancer Institute. 1988;80:1198–202.

13. Anand RG, Ventura HO, Mehra MR. Is heart failure more prevalent in patients with peripheral arterial disease? A meta-analysis. Congestive Heart Failure. 2007;13:319–22.

14. Kelly R, Staines A, MacWalter R, Stonebridge P, Tunstall-Pedoe H, Struthers AD. The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-control study. J Am Coll Cardiol. 2002;39:219–24.

15. Ward RP, Min JK, McDonough KM, Lang RM. High prevalence of important cardiac findings in patients with peripheral arterial disease referred for echocardiography. J Am Soc Echocardiogr. 2005;18:844–9.

16. Jeremias A, Gruberg L, Patel J, Connors G, Brown DL. Effect of peripheral arterial disease on inhospital outcomes after primary percutaneous coronary intervention for acute myocardial infarction. The American journal of cardiology. 2010;105:1268–71.

17. Inglis SC, Hermis A, Shehab S, Newton PJ, Lal S, Davidson PM. Peripheral arterial disease and chronic heart failure: a dangerous mix. Heart Fail Rev. 2013;18:457–64.

18. Yamasaki S, Izawa A, Shiba Y, et al. Presence of diastolic dysfunction in patients with peripheral artery disease. Angiology. 2013;64:540–3.

19. Yanaka K, Akahori H, Imanaka T, et al. The impact of peripheral artery disease on left ventricular diastolic function. Journal of cardiology. 2019;73:453–8.

20. D’Andrea A, Vriz O, Ferrara F, et al. Reference ranges and physiologic variations of left E/e’ratio in healthy adults: Clinical and echocardiographic correlates. Journal of cardiovascular echography. 2018;28:101.

21. Fowkes FGR, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. The Lancet. 2013;382:1329–40.

22. Andersen OS, Smiseth OA, Dokainish H, et al. Estimating left ventricular filling pressure by echocardiography. J Am Coll Cardiol. 2017;69:1937–48.

23. Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation. 2017;135:825–38.

24. Hillis GS, Møller JE, Pellikka PA, et al. Noninvasive estimation of left ventricular filling pressure by E/e’ is a powerful predictor of survival after acute myocardial infarction. J Am Coll Cardiol. 2004;43:360–7.

Figures
Figure 1

Kaplan-Meier curves showing freedom from death (A) and cardiovascular events (B) according to ejection fraction. CV, cardiovascular; EF, ejection fraction
Figure 2

Forest plot displaying hazard ratios predicting all-cause death (A) and major cardiovascular events (B). Red dots show significant prognostic factors for death and major cardiovascular events (p < 0.01). BP, blood pressure; CKD, chronic kidney disease; EF, ejection fraction; ICU, intensive care unit; LV, left ventricle; PASP, pulmonary artery systolic pressure.
Figure 3

A smooth nonlinear relationship between $E/e'$ and outcome in a regression model.
Figure 4

Kaplan-Meier curves showing freedom from death (A) and cardiovascular events (B) according to E/e’ among all patients PAD. CV, cardiovascular; PAD, peripheral arterial disease.
Figure 5

Kaplan-Meier curves showing freedom from death (A) and cardiovascular events (B) according to E/e among patients with preserved ejection fraction. EF, ejection fraction

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryTables.docx